×

Therapeutic agent for keratoconjunctival disorder

  • US 7,358,255 B2
  • Filed: 10/22/2004
  • Issued: 04/15/2008
  • Est. Priority Date: 10/24/2003
  • Status: Expired due to Fees
First Claim
Patent Images

1. A method for treating a keratoconjunctival disorder which comprises administering a therapeutically effective amount of 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione or a pharmaceutically acceptable salt thereof to a patient in need thereof.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×